Tiffany Chiu is the Vice President of Communications at AbCellera. Working with AbCellera’s teams across four countries and three continents, Tiffany oversees a global portfolio that includes executive and corporate communications, media and public relations, investor relations, marketing, and scientific communications. Tiffany led communications for AbCellera’s US $555 million listing on the Nasdaq, which was the largest biotech initial public offering in Canadian history. Tiffany also led communications during AbCellera’s pandemic response for COVID-19, where the company discovered two treatments for COVID-19, including the world’s first monoclonal antibody therapy authorized by the US FDA. To date, AbCellera’s COVID-19 antibodies have been used to treat an estimated 2.5 million patients, saving thousands of lives.
Before joining AbCellera, Tiffany co-founded Centrifuge Media Lab, a communications firm for leading biotech, life science, and tech organizations. Tiffany’s past roles also include Global Communications Lead for Accenture at Best Buy Canada and senior roles in the STEMCELL Group of Companies. She currently serves on the board of the Spring for Kids Foundation and is the past president and board member of the Vancouver Asian Canadian Theatre. Tiffany completed her BSc in Integrated Science from the University of British Columbia.